Work

AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

Year: 2022

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)01255-1

Authors: Keith W. Pratz, Mohamad Cherry, Nikolai A. Podoltsev, Jessica K. Altman, Alexander E. Perl, Brenda W. Cooper, Joseph G. Jurcic, Tara L. Lin, Gary J. Schiller, Ruishan Wu, Jason E. Hill, Stanley C. Gill, Angela James, Elizabeth Shima Rich, Nahla Hasabou, Mark J. Levis

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma, Yale University, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Abramson Cancer Center, University of Pennsylvania, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Columbia University Irving Medical Center, University of Kansas Medical Center, University of California, Los Angeles, Astellas Pharma (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296533008

Cites:

Cited by: 1

Related to: 10